{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:44:48Z","timestamp":1760150688301,"version":"build-2065373602"},"reference-count":43,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["11832003"],"award-info":[{"award-number":["11832003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>(1) Background: To evaluate the predictive value of Holter monitoring for overall survival (OS) of patients with light chain amyloidosis (AL amyloidosis). (2) Methods: 137 patients with newly diagnosed AL amyloidosis who underwent Holter monitoring within 6 months of diagnosis were included. The primary outcome was OS. Landmark analysis was conducted at one-year follow-up. Independent predictors were determined using the log-rank test and multivariate Cox regression analysis. (3) Results: 131 (95.6%) patients received non-transplant therapy, and 32 (23.4%) underwent daratumumab-based chemotherapy. After a median follow-up of 20.3 months, 47 deaths occurred. Atrial tachycardia (AT), conduction delay, and non-sustained ventricular tachycardia (NSVT) were associated with poor OS one year beyond diagnosis in univariate analyses (patients with vs. without AT: 57.3% [95% confidence interval (CI): 47.2\u201367.4] vs. 81.0% (95% CI: 74.8\u201387.2), p = 0.039; patients with vs. without NSVT: 33.3% (95% CI: 8.5\u201358.1) vs. 75.3% (95% CI: 69.8\u201380.8), p = 0.024; patients with vs. without conduction delay: 41.7% (95% CI: 24.4\u201359.0) vs. 75.4% (95% CI: 69.7\u201381.1), p = 0.003]. AT [hazard ratio (HR): 2.6; 95% CI: 1.0\u20136.5; p = 0.049) and conduction delay (HR: 4.3; 95% CI: 1.3\u201314.3; p = 0.016) were independent predictors of OS after accounting for age and 2012 Mayo stage. (4) Conclusion: AT and conduction delay in Holter monitoring are independent predictors of poor OS one year beyond diagnosis in AL amyloidosis.<\/jats:p>","DOI":"10.3390\/jcm12237457","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T08:36:59Z","timestamp":1701419819000},"page":"7457","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Value of Holter Monitoring in Light Chain Amyloidosis"],"prefix":"10.3390","volume":"12","author":[{"given":"Yutong","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Cardiology, Peking University People\u2019s Hospital, Beijing 100044, China"},{"name":"Center for Cardiovascular Translational Research, Peking University People\u2019s Hospital, Beijing 100044, China"},{"name":"Beijing Key Laboratory of Early Prediction and Intervention of Acute Myocardial Infarction, Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinghao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Peking University People\u2019s Hospital, Beijing 100044, China"},{"name":"Center for Cardiovascular Translational Research, Peking University People\u2019s Hospital, Beijing 100044, China"},{"name":"Beijing Key Laboratory of Early Prediction and Intervention of Acute Myocardial Infarction, Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking University People\u2019s Hospital, Beijing 100044, China"},{"name":"Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking University People\u2019s Hospital, Beijing 100044, China"},{"name":"Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuelin","family":"Dou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking University People\u2019s Hospital, Beijing 100044, China"},{"name":"Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5004-2741","authenticated-orcid":false,"given":"Jin","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking University People\u2019s Hospital, Beijing 100044, China"},{"name":"Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Peking University People\u2019s Hospital, Beijing 100044, China"},{"name":"Center for Cardiovascular Translational Research, Peking University People\u2019s Hospital, Beijing 100044, China"},{"name":"Beijing Key Laboratory of Early Prediction and Intervention of Acute Myocardial Infarction, Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"ref_1","first-page":"45","article-title":"Primary Systemic Amyloidosis: Clinical and Laboratory Features in 474 Cases","volume":"32","author":"Kyle","year":"1995","journal-title":"Semin. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/ajh.21934","article-title":"Immunoglobulin Light Chain Amyloidosis: 2011 Update on Diagnosis, Risk-Stratification, and Management","volume":"86","author":"Gertz","year":"2011","journal-title":"Am. J. Hematol."},{"key":"ref_3","first-page":"67","article-title":"Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Kumar","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1200\/JCO.2010.32.2271","article-title":"Amyloidosis: Pathogenesis and New Therapeutic Options","volume":"29","author":"Merlini","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European Collaborative Study of Cyclophosphamide, Bortezomib, and Dexamethasone in Upfront Treatment of Systemic AL Amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/leu.2017.286","article-title":"Clinical Presentation and Outcomes in Light Chain Amyloidosis Patients with Non-Evaluable Serum Free Light Chains","volume":"32","author":"Sidana","year":"2018","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev-med-052918-020140","article-title":"Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable","volume":"71","author":"Rubin","year":"2020","journal-title":"Annu. Rev. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1161\/01.CIR.0000034511.06350.DF","article-title":"Atrial Amyloidosis: An Arrhythmogenic Substrate for Persistent Atrial Fibrillation","volume":"106","author":"Peters","year":"2002","journal-title":"Circulation"},{"key":"ref_10","first-page":"128","article-title":"Atrial Fibrillation and Subtype of Atrial Fibrillation in Cardiac Amyloidosis: Clinical and Echocardiographic Features, Impact on Mortality","volume":"26","author":"Sanchis","year":"2019","journal-title":"Amyloid Int. J. Exp. Clin. Investig. Off. J. Int. Soc. Amyloidosis"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0735-1097(97)00267-2","article-title":"Electrophysiologic Abnormalities in AL (Primary) Amyloidosis with Cardiac Involvement","volume":"30","author":"Reisinger","year":"1997","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.hrthm.2015.09.016","article-title":"Electrophysiologic Assessment of Conduction Abnormalities and Atrial Arrhythmias Associated with Amyloid Cardiomyopathy","volume":"13","author":"Barbhaiya","year":"2016","journal-title":"Heart Rhythm"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.amjcard.2009.05.040","article-title":"Frequencies and Types of Arrhythmias in Patients with Systemic Light-Chain Amyloidosis with Cardiac Involvement Undergoing Stem Cell Transplantation on Telemetry Monitoring","volume":"104","author":"Goldsmith","year":"2009","journal-title":"Am. J. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/anec.12032","article-title":"Prevalence and Prognostic Value of Conduction Disturbances at the Time of Diagnosis of Cardiac AL Amyloidosis","volume":"18","author":"Boldrini","year":"2013","journal-title":"Ann. Noninvasive Electrocardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/0002-9343(77)90870-1","article-title":"The Conduction System in Cardiac Amyloidosis. Clinical and Pathologic Features of 23 Patients","volume":"62","author":"Ridolfi","year":"1977","journal-title":"Am. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1046\/j.1460-9592.2001.01228.x","article-title":"Holter Monitoring in AL Amyloidosis: Prognostic Implications","volume":"24","author":"Palladini","year":"2001","journal-title":"Pacing Clin. Electrophysiol."},{"key":"ref_17","first-page":"455","article-title":"Prognostic Significance of Holter Moni-tor Findings in Patients with Light Chain Amyloidosis","volume":"94","author":"Sidana","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis","volume":"38","author":"Kastritis","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood.2019000834","article-title":"A Prospective Observational Study of 915 Patients with Systemic AL Amyloidosis Treated with Upfront Bortezomib","volume":"134","author":"Manwani","year":"2019","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/bjh.18733","article-title":"First Report of Outcomes in Patients with Stage IIIb AL Amyloidosis Treated with Dara-VCD Front-Line Therapy","volume":"201","author":"Chakraborty","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_22","first-page":"99","article-title":"Classification of amyloidosis by laser micro-dissection and mass spectrometry based proteomic analysis","volume":"36","author":"Shen","year":"2015","journal-title":"Zhong Hua Xue Ye Xue Za Zhi"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Sun, W., Sun, J., Zou, L., Shen, K., Zhong, D., Zhou, D., Sun, W., and Li, J. (2015). The Successful Diagnosis and Typing of Systemic Amyloidosis Using A Microwave-Assisted Filter-Aided Fast Sample Preparation Method and LC\/MS\/MS Analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0127180"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_25","first-page":"e382","article-title":"2018 ACC\/AHA\/HRS Guideline on the Evaluation and Management of Patients with Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"140","author":"Kusumoto","year":"2019","journal-title":"Circulation"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/eurheartj\/ehz467","article-title":"2019 ESC Guidelines for the Management of Patients with Supraventricular tachycardia The Task Force for the Management of Patients with Supra-ventricular Tachycardia of the European Society of Cardiology (ESC)","volume":"41","author":"Brugada","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","article-title":"Analysis of Survival by Tumor Response","volume":"1","author":"Anderson","year":"1983","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","article-title":"Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis","volume":"128","author":"Griffin","year":"2021","journal-title":"Circ. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1002\/ejhf.2650","article-title":"Atrial Amyloidosis: Mechanisms and Clinical Manifestations","volume":"24","author":"Vergaro","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","article-title":"Atrial Fibrillation in Transthyretin Cardiac Amyloidosis: Predictors, Preva-lence, and Efficacy of Rhythm Control Strategies","volume":"6","author":"Donnellan","year":"2020","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcmg.2021.06.022","article-title":"Clinical Importance of Left Atrial Infiltration in Cardiac Transthyretin Amyloidosis","volume":"15","author":"Bandera","year":"2022","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","article-title":"Intracardiac Thrombosis and Embolism in Patients with Cardiac Amyloidosis","volume":"116","author":"Feng","year":"2007","journal-title":"Circulation"},{"key":"ref_33","first-page":"12","article-title":"Arterial Thrombo-Embolic Events in Cardiac Amyloidosis: A Look beyond Atrial Fibrillation","volume":"28","author":"Cappelli","year":"2021","journal-title":"Amyloid Int. J. Exp. Clin. Investig. Off. J. Int. Soc. Amyloidosis"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaccao.2021.07.010","article-title":"Electrophysiological Manifestations of Cardiac Amyloidosis: JACC: Cardio Oncology State-of-the-Art Review","volume":"3","author":"Hartnett","year":"2021","journal-title":"JACC Cardio Oncol."},{"key":"ref_36","first-page":"78","article-title":"Electrocardiographic Features and Need for Pacemaker in Cardiac Amyloidosis: Analysis of 58 Cases","volume":"159","year":"2022","journal-title":"Med. Clin."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic Cardiac Amyloidosis: Disease Profiles and Clinical Courses of the 3 Main Types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/ejhf.2533","article-title":"Incidence and Risk Factors for Pacemaker Implantation in Light-Chain and Transthyretin Cardiac Amyloidosis","volume":"24","author":"Porcari","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.cjca.2019.12.002","article-title":"Use of Implantable Electronic Devices in Patients with Cardiac Amyloidosis","volume":"36","author":"John","year":"2020","journal-title":"Can. J. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.cjca.2019.11.039","article-title":"Arrhythmias in Cardiac Amyloidosis: Challenges in Risk Stratification and Treatment","volume":"36","author":"Cheung","year":"2020","journal-title":"Can. J. Cardiol."},{"key":"ref_41","first-page":"3","article-title":"Guidelines for Non-Transplant Chemotherapy for Treatment of Systemic AL Amyloidosis: EHA-ISA Working Group","volume":"30","author":"Wechalekar","year":"2023","journal-title":"Amyloid Int. J. Exp. Clin. Investig. Off. J. Int. Soc. Amyloidosis"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"m441","DOI":"10.1136\/bmj.m441","article-title":"Calculating the Sample Size Required for Developing a Clinical Prediction Model","volume":"368","author":"Riley","year":"2020","journal-title":"BMJ"},{"key":"ref_43","unstructured":"Ensor, J., Martin, E.C., and Riley, R.D. (2023, October 19). Pmsampsize: Calculates the Minimum Sample Size Required for Developing a Multivariable Prediction Model. Available online: https:\/\/cran.r-project.org\/web\/packages\/pmsampsize\/index.html."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/23\/7457\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:36:01Z","timestamp":1760132161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/23\/7457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":43,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["jcm12237457"],"URL":"https:\/\/doi.org\/10.3390\/jcm12237457","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}